by Walter and Eliza Hall Institute of Medical Research Graphical abstract. Credit: Gastroenterology (2022). DOI: 10.1053/j.gastro.2022.08.040 WEHI researchers have revealed that common liver diseases are not driven by inflammatory cell death as previously thought, resolving a long-standing controversy in gastroenterology and pointing to a new direction for treatment. The research team studied liver diseases that affect billions...
by Elsevier Overview of hepatic proteomic and phosphoproteomic signatures identified in alcohol-associated hepatitis (AH) and alcohol-associated cirrhosis (AC). Hepatic neutrophils and chemoattractants are reduced in later stages of AH. Cardiolipin synthesis is compromised in AH and AC. These are newly identified metabolic defects and are likely to lead to the development/progression of AH/AC. Credit: American Journal...
by Massachusetts General Hospital Association of medical addiction therapy for alcohol use disorder with odds of hepatic decompensation within 10 years after cirrhosis diagnosis. Credit: JAMA Network Open (2022). DOI: 10.1001/jamanetworkopen.2022.13014 Excessive alcohol consumption can harm the liver, causing a range of conditions from relatively minor liver damage to serious problems such as cirrhosis and liver cancer—all...
THE ENDOCRINE SOCIETY WASHINGTON—Women with long or irregular periods are known to have a higher risk of type 2 diabetes and heart disease, but researchers found these women may also be at risk for nonalcoholic fatty liver disease (NAFLD), according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology and Metabolism. About...
by Melissa Rohman, Northwestern University Graphical abstract. Credit: DOI: 10.1016/j.molcel.2021.10.028 Northwestern Medicine investigators have discovered the molecular mechanisms underlying a rare genetic mutation that increases the risk of severe liver disease, according to findings published in Molecular Cell. The study, led by Deyu Fang, Ph.D., the Hosmer Allen Johnson Professor of Pathology, may reveal potential therapeutic...
by Monash University Credit: CC0 Public Domain A cell therapy could reduce inflammatory response in liver disease, offering hope to thousands of Australians suffering from the disease. Inflammation underpins hundreds of health conditions, contributing to more than 50 percent of deaths worldwide, and Hudson Institute has Australia’s largest team of inflammation researchers, whose sole focus is...
by University of Tsukuba Credit: WAKIMOTO Arata Non-alcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver unrelated to alcohol abuse or other liver diseases. It is often associated with obesity and diabetes and is considered a manifestation of metabolic syndrome. It progresses into non-alcoholic steatohepatitis (NASH) with the onset of inflammation,...
by University of Southern California Credit: Pixabay/CC0 Public Domain About 80 million Americans have fatty liver disease unrelated to alcohol abuse. Nonalcoholic fatty liver disease is associated with obesity and diabetes, and can lead to more severe liver damage such as nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Cardiovascular disease, colorectal cancer, and breast cancer...
by University of California, Los Angeles Schematic representation of m6A modifications (blue) attaching to RNA in the liver. Credit: Sallam Lab/UCLA A chemical modification that occurs in some RNA molecules as they carry genetic instructions from DNA to cells’ protein-making machinery may offer protection against non-alcoholic fatty liver, a condition that results from a build-up of...
by Helmholtz Association of German Research Centres Credit: Helmholtz Zentrum München – German Research Center for Environmental Health Non-alcoholic fatty liver disease is the most common liver disorder worldwide and is present in approximately 25 percent of the world’s population. Over 90 percent of obese, 60 percent of diabetic, and up to 20 percent of normal-weight people develop...
